Use of pharmacoeconomics in prescribing research. Part 1: costs - moving beyond the acquisition price for drugs
- 28 February 2003
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 28 (1), 73-79
- https://doi.org/10.1046/j.1365-2710.2003.00452.x
Abstract
This paper addresses pharmacoeconomics in prescribing research and reflects the increasing use of techniques of economic evaluation to aid drug purchasing decisions in a variety of settings – for national drug subsidization programmes, provincial purchasing plans, insurance programmes, and for hospital and area health authority formulary decisions. First, we focus on the cost component of an economic evaluation and discuss methodological issues that are relevant to all pharmacoeconomic analyses.Keywords
This publication has 8 references indexed in Scilit:
- Introduction to health economics for physiciansThe Lancet, 2001
- A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.PharmacoEconomics, 2001
- Economics notes: Costing in economic evaluationBMJ, 2000
- Problems With the Interpretation of Pharmacoeconomic AnalysesJAMA, 2000
- Economics notes: DiscountingBMJ, 1999
- Economics notes: Handling uncertainty in economic evaluationBMJ, 1999
- Economics notes: Opportunity costBMJ, 1999
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996